A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E2 levels as a biomarker

Dory Sample, Michael J Wargovich, Susan M. Fischer, Nikil Inamdar, Peter Schwartz, Xuemei Wang, Kim Anh Do, Frank A. Sinicrope

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Epidemiological and experimental evidence indicates that aspirin can protect against colorectal cancer. Aspirin inhibits cyclooxygenase enzymes and blocks prostaglandin (PG) biosynthesis. Using rectal PGE2 levels as a mucosal biomarker, we sought to determine the optimal aspirin dose that would significantly suppress PGE2 levels for chemoprevention trials. We conducted a randomized, double-blinded study in 60 subjects with prior sporadic colorectal adenoma(s) and evaluated three aspirin doses (81, 325, and 650 mg) or placebo taken daily for 4 weeks. PGE2 levels in rectal biopsies performed at baseline and week 4 were analyzed by competitive immunoassay. Plasma salicylate levels, pill counts, and subject calendars were used to assess compliance. The 81-mg aspirin dose significantly suppressed PGE2 levels relative to placebo (P = 0.005) and did so to an equivalent extent as did higher doses (P > 0.4) in evaluable subjects (n = 55) over a 4-week treatment period. Serum salicylate levels were associated with aspirin dose (P = 0.0002). Pill counts and calendars indicated that >98% of doses were taken by all subjects. No adverse events occurred in this short-term study. The 81-mg daily aspirin dose suppressed PGE2 levels to an equivalent extent as did the 650-mg dose and supports the use of this dose for chemoprevention trials.

Original languageEnglish (US)
Pages (from-to)275-279
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume11
Issue number3
StatePublished - 2002
Externally publishedYes

Fingerprint

Chemoprevention
Dinoprostone
Aspirin
Biomarkers
Salicylates
Placebos
Prostaglandin-Endoperoxide Synthases
Immunoassay
Adenoma
Compliance
Prostaglandins
Colorectal Neoplasms
Biopsy
Enzymes
Serum

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E2 levels as a biomarker. / Sample, Dory; Wargovich, Michael J; Fischer, Susan M.; Inamdar, Nikil; Schwartz, Peter; Wang, Xuemei; Do, Kim Anh; Sinicrope, Frank A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 11, No. 3, 2002, p. 275-279.

Research output: Contribution to journalArticle

Sample, D, Wargovich, MJ, Fischer, SM, Inamdar, N, Schwartz, P, Wang, X, Do, KA & Sinicrope, FA 2002, 'A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E2 levels as a biomarker', Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 3, pp. 275-279.
Sample, Dory ; Wargovich, Michael J ; Fischer, Susan M. ; Inamdar, Nikil ; Schwartz, Peter ; Wang, Xuemei ; Do, Kim Anh ; Sinicrope, Frank A. / A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E2 levels as a biomarker. In: Cancer Epidemiology Biomarkers and Prevention. 2002 ; Vol. 11, No. 3. pp. 275-279.
@article{3359e6587e7b4ce2ae7fd8ba8561ddd1,
title = "A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E2 levels as a biomarker",
abstract = "Epidemiological and experimental evidence indicates that aspirin can protect against colorectal cancer. Aspirin inhibits cyclooxygenase enzymes and blocks prostaglandin (PG) biosynthesis. Using rectal PGE2 levels as a mucosal biomarker, we sought to determine the optimal aspirin dose that would significantly suppress PGE2 levels for chemoprevention trials. We conducted a randomized, double-blinded study in 60 subjects with prior sporadic colorectal adenoma(s) and evaluated three aspirin doses (81, 325, and 650 mg) or placebo taken daily for 4 weeks. PGE2 levels in rectal biopsies performed at baseline and week 4 were analyzed by competitive immunoassay. Plasma salicylate levels, pill counts, and subject calendars were used to assess compliance. The 81-mg aspirin dose significantly suppressed PGE2 levels relative to placebo (P = 0.005) and did so to an equivalent extent as did higher doses (P > 0.4) in evaluable subjects (n = 55) over a 4-week treatment period. Serum salicylate levels were associated with aspirin dose (P = 0.0002). Pill counts and calendars indicated that >98{\%} of doses were taken by all subjects. No adverse events occurred in this short-term study. The 81-mg daily aspirin dose suppressed PGE2 levels to an equivalent extent as did the 650-mg dose and supports the use of this dose for chemoprevention trials.",
author = "Dory Sample and Wargovich, {Michael J} and Fischer, {Susan M.} and Nikil Inamdar and Peter Schwartz and Xuemei Wang and Do, {Kim Anh} and Sinicrope, {Frank A.}",
year = "2002",
language = "English (US)",
volume = "11",
pages = "275--279",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E2 levels as a biomarker

AU - Sample, Dory

AU - Wargovich, Michael J

AU - Fischer, Susan M.

AU - Inamdar, Nikil

AU - Schwartz, Peter

AU - Wang, Xuemei

AU - Do, Kim Anh

AU - Sinicrope, Frank A.

PY - 2002

Y1 - 2002

N2 - Epidemiological and experimental evidence indicates that aspirin can protect against colorectal cancer. Aspirin inhibits cyclooxygenase enzymes and blocks prostaglandin (PG) biosynthesis. Using rectal PGE2 levels as a mucosal biomarker, we sought to determine the optimal aspirin dose that would significantly suppress PGE2 levels for chemoprevention trials. We conducted a randomized, double-blinded study in 60 subjects with prior sporadic colorectal adenoma(s) and evaluated three aspirin doses (81, 325, and 650 mg) or placebo taken daily for 4 weeks. PGE2 levels in rectal biopsies performed at baseline and week 4 were analyzed by competitive immunoassay. Plasma salicylate levels, pill counts, and subject calendars were used to assess compliance. The 81-mg aspirin dose significantly suppressed PGE2 levels relative to placebo (P = 0.005) and did so to an equivalent extent as did higher doses (P > 0.4) in evaluable subjects (n = 55) over a 4-week treatment period. Serum salicylate levels were associated with aspirin dose (P = 0.0002). Pill counts and calendars indicated that >98% of doses were taken by all subjects. No adverse events occurred in this short-term study. The 81-mg daily aspirin dose suppressed PGE2 levels to an equivalent extent as did the 650-mg dose and supports the use of this dose for chemoprevention trials.

AB - Epidemiological and experimental evidence indicates that aspirin can protect against colorectal cancer. Aspirin inhibits cyclooxygenase enzymes and blocks prostaglandin (PG) biosynthesis. Using rectal PGE2 levels as a mucosal biomarker, we sought to determine the optimal aspirin dose that would significantly suppress PGE2 levels for chemoprevention trials. We conducted a randomized, double-blinded study in 60 subjects with prior sporadic colorectal adenoma(s) and evaluated three aspirin doses (81, 325, and 650 mg) or placebo taken daily for 4 weeks. PGE2 levels in rectal biopsies performed at baseline and week 4 were analyzed by competitive immunoassay. Plasma salicylate levels, pill counts, and subject calendars were used to assess compliance. The 81-mg aspirin dose significantly suppressed PGE2 levels relative to placebo (P = 0.005) and did so to an equivalent extent as did higher doses (P > 0.4) in evaluable subjects (n = 55) over a 4-week treatment period. Serum salicylate levels were associated with aspirin dose (P = 0.0002). Pill counts and calendars indicated that >98% of doses were taken by all subjects. No adverse events occurred in this short-term study. The 81-mg daily aspirin dose suppressed PGE2 levels to an equivalent extent as did the 650-mg dose and supports the use of this dose for chemoprevention trials.

UR - http://www.scopus.com/inward/record.url?scp=0036227319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036227319&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 275

EP - 279

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -